News1 min read
Scaling CRISPR Gene Correction for Sickle Cell Disease
About this article
- Published
- Further reading
- The Medicine Maker(opens in a new tab)
A clinical-scale manufacturing process may enable direct correction of the mutation linked to sickle cell disease in patients' blood-forming stem cells.
Read the original report from The Medicine Maker.